2022
DOI: 10.1016/j.cpcardiol.2021.100847
|View full text |Cite
|
Sign up to set email alerts
|

Advanced Echocardiography Techniques: The Future Stethoscope of Systemic Diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
7
0
3

Year Published

2022
2022
2024
2024

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 12 publications
(10 citation statements)
references
References 166 publications
(156 reference statements)
0
7
0
3
Order By: Relevance
“…However, it gradually gained popularity as a global tool, that can diagnose early dysfunction in systemic disease, particularly in cardio-oncology. [5] Our case series revives the segmental power of STE and shows that it can differentiate pericarditis from myocarditis without resorting to costly and lengthy CMR.…”
Section: Discussionmentioning
confidence: 77%
“…However, it gradually gained popularity as a global tool, that can diagnose early dysfunction in systemic disease, particularly in cardio-oncology. [5] Our case series revives the segmental power of STE and shows that it can differentiate pericarditis from myocarditis without resorting to costly and lengthy CMR.…”
Section: Discussionmentioning
confidence: 77%
“…Furthermore, the evaluation of diastolic function and the STE-GLS analysis were performed only in a subset of the participants. Regarding the limitations of the echocardiographic methods used in the study, M-mode echocardiography is limited by angle-dependency, while the main limitation of STE is intervendor variability [ 50 , 51 ]. Moreover, interobserver and intraobserver variability were not assessed in our study.…”
Section: Resultsmentioning
confidence: 99%
“…Moreover, interobserver and intraobserver variability were not assessed in our study. Additionally, although, GLS is a very sensitive indicator of ventricular injury and is the most commonly used STE parameter in clinical practice, STE analysis was limited only in the evaluation of systolic function with longitudinal cardiac deformation assessment (GLS) and global circumferential and radial strain were not assessed [ 50 ]. Finally, we did not perform GLS with Cardiac Magnetic Resonance (CMR) imaging for comparison with the 2D-Ultrasound GLS results.…”
Section: Resultsmentioning
confidence: 99%
“…Despite the lack of massive evidence on patient selection, treatment efficacy, and economic impact, screening for subclinical left ventricular dysfunction in metabolic disease enables cardioprotective therapy to be implemented at an early stage to prevent or delay the progression of heart failure [ 8 ]. Such screening is expected to be increasingly feasible with miniaturized echocardiography equipment and automated analysis [ 20 , 21 ].…”
Section: Discussionmentioning
confidence: 99%